Connexin 43 peptidic medicine for glioblastoma stem cells

EBioMedicine. 2021 Feb:64:103205. doi: 10.1016/j.ebiom.2020.103205. Epub 2021 Jan 23.

Author

Zhi Sheng¹

Affiliation

¹ Fralin Biomedical Research Institute at VTC, Roanoke, VA 24016, United States; Department of Internal Medicine, Virginia Tech Carilion School of Medicine, Roanoke, VA 24016, United States; Faculty of Health Science, Virginia Tech, Blacksburg, VA 24061, United States. Electronic address: zhisheng@vtc.vt.edu.

No abstract available

Publication types

Letter

MeSH terms

Animals
Brain Neoplasms / drug therapy
Brain Neoplasms / etiology
Brain Neoplasms / metabolism
Brain Neoplasms / pathology
CSK Tyrosine-Protein Kinase / antagonists & inhibitors
Connexin 43 / chemistry
Connexin 43 / metabolism*
Glioblastoma / drug therapy
Glioblastoma / etiology
Glioblastoma / metabolism*
Glioblastoma / pathology
Humans
Neoplastic Stem Cells / drug effects*
Neoplastic Stem Cells / metabolism*
Peptides / pharmacology*
Peptides / therapeutic use
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use

Substances

Connexin 43
Peptides
Protein Kinase Inhibitors
CSK Tyrosine-Protein Kinase